Drug Trial Radar · NCT05490446
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
87
Actual
Start
Nov 7, 2022
Primary completion
Mar 17, 2026
Study completion Mar 2029
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Conditions
- Myelodysplastic Syndromes
Interventions
TebapivatDrug
Tebapivat Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2a: Proportion of Participants With Hemoglobin (Hb) ResponseTime frame: Baseline, Week 8 through Week 16
- Phase 2a: Proportion of Participants With Transfusion Independence During the Core PeriodTime frame: Up to 16 weeks
- Phase 2b: Proportion of Participants With Transfusion IndependenceTime frame: Up to 24 weeks
Locations
45 sites in 13 countries. Site status is shown where the registry gives one.
Innovative Clinical Research Institute Whittier
Lakewood, California
David Geffen School of Medicine at UCLA
Los Angeles, California
Emad Ibrahim, MD, Inc.
Redlands, California
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida
Edward H. Kaplan MD & Associates
Skokie, Illinois
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
Long Island City, New York
Duke Adult Blood and Marrow Clinic
Durham, North Carolina
Monash Health, Monash Medical Centre
Clayton, Victoria, Australia
Ordensklinikum Linz GmbH Elisabethinen
Linz, Upper Austria, Austria
Fakultni nemocnice Ostrava
Ostrava, Czechia
CHRU Lille
Lille, France
Hôpital Saint Louis
Paris, France
Hôpital de La Conception
Marseille, Bouches-du-Rhône, France
CHU Angers
Angers, Maine-et-Loire, France
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
Universitatsklinikum Dusseldorf
Düsseldorf, North Rhine-Westphalia, Germany
Universitatsklinikum Leipzig
Leipzig, Saxony, Germany
University Hospital of Alexandroupolis
Alexandroupoli, Greece
Attikon University General Hospital
Athens, Greece
University General Hospital of Patras
Pátrai, Greece
Hippokration Hospital
Thessaloniki, Greece
Shaare Zedek Medical Center
Jerusalem, Israel
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, Israel
Fondazione PTV Policlinico Tor Vergata
Roma, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Azienda Ospedaliera Ordine Mauriziano di Torino
Turin, Piedmont, Italy
MTZ Clinical Research Powered by PRATIA - PPDS
Warsaw, Masovian Voivodeship, Poland
Pratia Onkologia Katowice - PRATIA - PPDS
Katowice, Silesian Voivodeship, Poland
SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, Warmian-Masurian Voivodeship, Poland
Kyungpook National University Hospital
Daegu, South Korea
Asan Medical Center - PPDS
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
C.H. Regional Reina Sofia - PPDS
Córdoba, Spain
Hospital Universitario La Paz - PPDS
Madrid, Spain
Hospital Universitario HM Sanchinarro - CIOCC
Madrid, Spain
Complejo Asistencial Universitario de Salamanca - H. Clinico
Salamanca, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.